The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy.
B. Grana
No relevant relationships to disclose
H. A. Burris
No relevant relationships to disclose
J. Rodon Ahnert
No relevant relationships to disclose
A. R. Abdul Razak
No relevant relationships to disclose
M. J. De Jonge
No relevant relationships to disclose
F. Eskens
No relevant relationships to disclose
L. L. Siu
Research Funding - GlaxoSmithKline; Novartis; Pfizer
Q. C. Ru
Employment or Leadership Position - Novartis
N. F. Homji
Employment or Leadership Position - Novartis
D. Demanse
Employment or Leadership Position - Novartis
E. Di Tomaso
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
J. G. C. E. Cosaert
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
C. Quadt
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
J. Baselga
Consultant or Advisory Role - Novartis
J. C. Bendell
No relevant relationships to disclose